About 5 results found for searched term "QL9" (0.118 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3788 | HQL-79 | PGE synthase |
| HQL-79 is a selective inhibitor of human hematopoietic prostaglandin D (PGD) synthase (H-PGDS) (IC50 = 6 μM). | ||
| M43233 | QL9 TFA | Others |
| QL9 (QLSPFPFDL) TFA is a high-affinity alloantigen for the 2C T cell receptor (TCR). | ||
| M51481 | QL9 | Others |
| QL9 (QLSPFPFDL) is a high-affinity alloantigen for the 2C T cell receptor (TCR). | ||
| M21346 | Recombinant Human Cuteaneous T-cell Attracting Chemokine/CCL27 (E.coli ) | Cytokines and Growth Factors |
| AA Sequence：FLLPPSTACC TQLYRKPLSD KLLRKVIQVE LQEADGDCHL QAFVLHLAQR SICIHPQNPS LSQWFEHQER KLHGTLPKLN FGMLRKMG.Accession: Q9Y4X3. | ||
| M24799 | Elezanumab | TGF-beta/Smad |
| ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody | ||
| Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
